Intertox brings together the excellence and expertise of several CentraleSupélec and Gustave Roussy teams in the fields of complex and innovative predictive modeling, breast cancer survival, ethics, sociology and psychology.

Its aim is to improve quality of life (QoL) after cancer, in particular to understand the risk of treatment-related toxicities and how they affect patients' lives, but also to communicate with patients about these risks.

• Objective 1: Identify trajectories and biobehavioral risk factors for toxicity and QoL impairment after breast cancer;

• Objective 2: Determine how to better communicate the risk of toxicities and impairment of patients' QoL to pave the way for the use of models developed during Objective 1 in clinical practice. For Objective 1, a) a quantitative strategy involves building predictive risk models based on clinical, biological and patient-reported outcomes data from the CANcer TOxicities (CANTO) cohort, as well as b) iterative input from experts in the human and social sciences. For Objective 2, a qualitative study aimed at understanding how to communicate to patients the results of the models developed in Objective 1 will be implemented, using a state-of-the-art digital infrastructure, weSHARE.

Partners links to Paris-Saclay

• CentraleSupélec, MICS Laboratory
• INSERM Unit 981, Gustave Roussy
• CESP (Inserm, UPSay, UVSQ)
• Gustave Roussy

Other foreign partners

• Shoshana Rosenberg, BA, MPH, ScD, Harvard Medical School, focusing on breast cancer survivorship, quality of life and treatment decision-making, including decision aids. He co-supervised one of the post-doctoral researchers (N. 2): expertise in research dedicated to improving care for women with breast cancer (e.g. qualitative analyses in psychosocial studies, focusing on quality of life and cancer) contributing to the development of Objective 2.

Contacts : Paul-Henry COURNEDE | Antonio DI MEGLIO